Bovine Serum Albumin - Global Strategic Business Report

Global Bovine Serum Albumin Market to Reach $415.8 Million by 2030

The global market for Bovine Serum Albumin estimated at US$262 Million in the year 2022, is projected to reach a revised size of US$415.8 Million by 2030, growing at a CAGR of 5.9% over the analysis period 2022-2030. Dry, one of the segments analyzed in the report, is projected to record 5.5% CAGR and reach US$229.9 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Liquid segment is readjusted to a revised 6.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $76.6 Million, While China is Forecast to Grow at 5.7% CAGR

The Bovine Serum Albumin market in the U.S. is estimated at US$76.6 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$73.6 Million by the year 2030 trailing a CAGR of 5.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.7% and 5.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6% CAGR.

Select Competitors (Total 42 Featured) -

• Belhealth Investment Partners, LLC
• Biological Industries
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Itoham Yonekyu Holdings Inc.
• Kraeber & Co GmbH
• LGC Group
• Merck KGaA
• Proliant Biologicals
• Promega Corporation

What's New?

• Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and Research Platform
• Complimentary updates for one year